Mutational inactivation of NPC1 largely blocks the movement of LDL-derived cholesterol from the lysosome to the metabolically active, cytosolic pool of sterol that is the substrate for steroid hormone production. Such a block might, in theory, lead to deficiencies in circulating levels of testosterone, progesterone, and corticosterone. However, there are at least two other sources for cellular cholesterol, de novo synthesis and scavenger receptor class B type I-mediated uptake of HDL cholesteryl ester (CE). In this study, we measured the rates of net cholesterol acquisition by these three pathways in the adrenal, ovary, and testis. In all three organs, the majority (81-98%) of cholesterol acquisition came from the selective uptake of CE from HDL and de novo synthesis. Furthermore, in the npc1 2/2 mouse, the cytosolic storage pool of CE in a tissue such as the adrenal remained constant (z25 mg/g). As a result of these alternative pathways, the plasma concentrations of testosterone (3.5 vs. 2.5 ng/ml), progesterone (8.5 vs. 6.7 ng/ml), and corticosterone (391 vs. 134 ng/ml) were either the same or elevated in the npc1 2/2 mouse, compared with the control animal.Thus, impairment of cholesterol acquisition through the NPC1-dependent, clathrin-coated pit pathway did not limit the availability of cholesterol substrate for steroid hormone synthesis in the steroidogenic cells. Essentially all cells acquire cholesterol primarily through de novo synthesis (1-3). In addition, at least three different proteins located in the plasma membrane are recognized that can also bring about the net transfer of sterol from the extracellular environment into the metabolically active pools of cholesterol within these cells. The first of these, the LDL receptor (LDLR), can take up lipoproteins that contain one of two ligands, apolipoprotein B 100 (apoB 100 ) or apoE, and these include LDL and the remnants of both VLDL and chylomicrons (4, 5). This transport process involves binding of the ligand to the receptor, clustering of the bound lipoproteins into clathrin-coated pits, and finally, internalization of these particles into the endosomal/ lysosomal compartment of the cell (6). There, acidification leads to a change in the configuration of the binding site on the LDLR, release of the lipoprotein, and ultimately, hydrolysis of the cholesteryl ester (CE) contained in these particles by an acidic cholesteryl ester esterase, i.e., acid lipase (7-9). Thus, this LDLR-dependent endocytosis results in the uptake of the cholesterol, both esterified and unesterified, carried in particles like LDL, and deposits it as unesterified sterol in the endosomal compartment of the cell.The second plasma membrane protein, scavenger receptor class B type I (SR-BI), binds lipoproteins containing apoAI such as HDL, and then processes these particles through a very different pathway (10,11). Although the details of this internalization step are not clear, in some manner cholesteryl ester from the HDL particle is selectively translocated into the cell ...